We propose a model that describes the roles of Aurora kinase A and PLK1 over-expression and hyper-activation in signaling pathways that operate in CML cells and the effects of their inhibition. The gene discussed is PLK1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.